PerkinElmer

NOVEMBER 9, 2022

Immunotherapy has revolutionized cancer treatment and proved to be pivotal in the field of oncological research. These cells overexpress PD-L1, leading to inhibition of cytotoxic T-cells by binding to the PD-1 receptor on activated T-cells, and subsequent evasion of an immune response.

Small Molecule 52

Small Molecule Research Immune Response FDA Approval 52

Drug Target Review

NOVEMBER 6, 2023

Advances in research and development and the utilisation of combination treatment strategies are revolutionising the haematology care landscape, but more must be done to address patients’ individual needs. To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

Olympian Clinical Research

MAY 6, 2024

These targeted therapies revolutionized treatment, offering relief to severe cases by specifically addressing the underlying immune responses causing the disease. If you or someone you know is struggling with plaque psoriasis, consider contacting Olympian Clinical Research.

Treatment 52

Treatment Small Molecule Clinical Research Immune Response 52

Drug Target Review

JULY 7, 2023

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. This can create an abnormal immune response that attacks the cells of our bodies and contributes to the development of autoantibody diseases.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

Vial

DECEMBER 11, 2023

In the decades since its identification in 1989, advances in clinical research for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Target Review

DECEMBER 7, 2023

Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immune response.

RNA 59

RNA Immune Response DNA Molecular Biology 59

Drug Target Review

NOVEMBER 7, 2024

Agonist antibodies of immune checkpoint regulators These represent a groundbreaking class of immunotherapeutic agents that mimic the natural function of endogenous ligands by binding to specific cell-surface receptors. In these conditions, the goal of therapy is typically to suppress or mitigate immune activity.

Disease 52

Disease Immune Response Regulations Engineering 52

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Dark Matter Blog

JULY 16, 2021

Growing up in Shrewsbury, Massachusetts, it was natural for me to attempt to get a summer job up the road at the Worcester Foundation for Biomedical Research, where the first oral contraceptive was created. I am now at the end of a career that has comprised nearly 10 years of academic research and 35 years in biotechnology.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

The Premier Consulting Blog

APRIL 18, 2024

This is due to the high-risk nature of these kinds of products (especially for a first-in-class therapy) and the fact that some cell or gene therapies can only be administered once due to the development of immune responses to the drug product. Does it have input and buy-in from regulatory agencies?

Therapies 52

Therapies Clinical Trials Small Molecule Immune Response 52

The Pharma Data

MAY 15, 2023

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Executive Vice President, Research, Gilead Sciences. “The Executive Vice President, Research, Gilead Sciences.

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JANUARY 17, 2021

It was co-sponsored by Merck and Bayer, conducted with the scientific oversight of the Canadian VIGOUR Centre and the Duke Clinical Research Institute. By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. Aurinia Pharmaceutical’s Voclosporin for Lupus Nephritis.

FDA 52

FDA Small Molecule Immune Response Hospitals 52

The Pharma Data

APRIL 22, 2023

While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation. Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

PLOS: DNA Science

SEPTEMBER 5, 2024

Researchers from Harvard Medical School describe a new ChatGPT-like model that can guide clinical decision-making to diagnose, treat, and predict survival for several types of cancer. A name ending in “nib” means a small molecule that inhibits an enzyme called a kinase, and is short for “inhibit.”

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

Drug Target Review

JULY 11, 2023

In the quest to combat and eradicate diseases, scientists and researchers are increasingly turning to the immense potential of artificial intelligence (AI) as a tool. In this way, the platform inverts the traditional target-led discovery process, and allows the immune system to guide us to the most importantdisease modifying target.

Disease 75

Disease RNA Small Molecule Clinical Development 75

LifeSciVC

MARCH 1, 2023

Luke, all with the UPMC Hillman Cancer Center at the University of Pittsburgh, summarized the challenges previously encountered in targeting costimulatory pathways and the compelling scientific rationale for targeting CBL-B as a master regulator of the immune system that is downstream of proven mechanisms like CD28, CTLA4 and PD1.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

OCTOBER 27, 2020

Mirati Therapeutics is a San Diego -based late-stage biotechnology company relentlessly focused on translating drug discovery and research into new treatments for patients by advancing and delivering novel therapeutics that target the genetic and immunologic drivers of cancer. About Mirati Therapeutics.

Small Molecule 52

Small Molecule Immune Response Clinical Development Clinical Trials 52

The Pharma Data

DECEMBER 15, 2020

However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The human monoclonal antibody targets specific immune plasma cells. Small Molecule Inhibitors.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

NIH Director's Blog: Drug Development

MAY 21, 2020

In a recent paper in the journal Science , researchers used blood drawn from a COVID-19 survivor to identify a pair of previously unknown antibodies that specifically block SARS-CoV-2 from attaching to human cells [2]. They were then able to produce many identical copies of each antibody, referred to as monoclonal antibodies.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

OCTOBER 27, 2020

AavantiBio’s strategic partnership with University of Florida’s Powell Gene Therapy Center provide their foundational research in rare genetic disorders. Primmune aims to advance the development of their novel orally-administered, small molecule toll-like receptor 7 agonists as therapeutic-adjuvants for acute viral diseases and cancer.

Small Molecule 52

Small Molecule Immune Response Therapies Clinical Development 52

The Pharma Data

FEBRUARY 22, 2021

In necroptosis, cells rupture leading to the dispersion of cell contents which can trigger an immune response and enhance inflammation. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. vice president of immunology at Lilly. Rigel Pharmaceuticals, Inc.,

Clinical Development 40

Clinical Development Small Molecule Clinical Trials Immune Response 40

New Drug Approvals

DECEMBER 16, 2023

3 Additionally, iptacopan has the benefit of targeting factor B, which only affect the alternative complement pathway, leaving the classic and lectin pathway untouched for the body to still mount adequate immune responses against pathogens. of patients experienced a sustained hemoglobin improvement without transfusions respectively.

FDA 62

FDA Small Molecule FDA Approval Treatment 62

Agency IQ

JUNE 9, 2023

However, this guideline is primarily intended to provide recommendations on evaluating the immune system’s response to small molecule drugs. The guidance contains recommendations for small molecule drugs, as well as any biological products that fall within CDER’s purview.

FDA 40

FDA Small Molecule Science Immune Response 40

Codon

AUGUST 27, 2024

Identifying a new or unexpected pathogen quickly, particularly when it occurs in conjunction with other, more common illnesses, is a key challenge for doctors, researchers, and public health professionals concerned with disease preparedness and biosecurity. Cite: Allison Berke. “Defense-Forward Biosecurity.” DOI: [link]

DNA 83

DNA Laboratories Hospitals Virus 83

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 20, 2020

efficacy, according to the state-run Gamaleya research center and the Russian Direct Investment Fund (RDIF). The data demonstrated the vaccine elicited a combined adaptive humoral and cellular immune response and also provided insights into the composite nature of BNT162b2-induced T-cell immunity.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

Drug Target Review

DECEMBER 13, 2024

However, research and clinical trials of BiTEs in solid tumours, including NSCLC, are still in the early phases. As research advances and new technologies emerge, the potential to transform lung cancer into a more manageable condition could be on the horizon, marking a new era in the fight against this disease. Biomarker Research.

Therapies 52

Therapies Treatment Clinical Trials Drugs 52

The Pharma Data

SEPTEMBER 9, 2020

Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We producing CD8+ T cell responses, which is thought to promote an anti-viral effect. In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, Jansen, Ph.D.,

Vaccine 52

Vaccine RNA Clinical Trials Trials 52

Codon

DECEMBER 12, 2024

Among the report’s authors are 16 members of national academies, two Nobel Laureates, and several researchers who have previously been frontrunners in the quest to create mirrored life. ” 1 Now, it seems, these researchers have changed their minds. Then there’s the cost.

DNA 81

DNA RNA Vaccine Virus 81

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

Codon

APRIL 30, 2023

This study sheds light on how, exactly, AI-generated text differs from the real stuff, and how it could be used to (soon) write entire research papers. In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Cell Systems.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

This study sheds light on how, exactly, AI-generated text differs from the real stuff, and how it could be used to (soon) write entire research papers. In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Cell Systems.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

SEPTEMBER 9, 2020

During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response.

Vaccine 52

Vaccine Clinical Trials Trials Government 52

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. THERAPEUTIC AREAS OF FOCUS. mg/dL at doses of 15, 70 and 120 mg respectively, compared to a -24.8

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

DECEMBER 27, 2020

Reporting encouraging preliminary Phase 1 clinical study results with VAC2 for the treatment of non-small cell lung cancer with high levels of antigen-specific immunogenicity observed.

Therapies 40

Therapies Clinical Trials Production Treatment 40

The Pharma Data

AUGUST 3, 2021

– Second-quarter 2021 operating expenses increased 18 percent, driven primarily by higher research and development investments for late-stage assets, as well as higher relative marketing and selling expenses due to pandemic-related spending reductions in 2020. – Second-quarter 2021 earnings per share (EPS) decreased to $1.53

Production 52

Production Marketing Research DNA 52